SABCS 2024 | COMET: patient-reported outcomes in active monitoring versus GCC for DCIS

Puneet Singh • 13 Dec 2024

SABCS 2024

Breast Cancer

COMET

Puneet Singh, MD, MS, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of the patient-reported outcomes (PROs) from the COMET trial (NCT02926911), which compared active monitoring (AM) with surgical management in low-risk ductal carcinoma in situ (DCIS). No significant negative outcomes were reported regardless of treatment arms, providing valuable insights into patient-centered care for low-risk DCIS. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.